First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma

August 2019 Vol 10, No 8

First-line therapy with pembrolizumab plus axitinib significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib in patients with clear cell metastatic renal cell carcinoma (RCC) in KEYNOTE-426. The combination of pembrolizumab plus axitinib achieved a significant 47% reduction in mortality risk versus sunitinib (P <.0001).

The benefits of the combination were seen across the board in all patient subgroups.

“These results are exciting. By adding the checkpoint inhibitor pembrolizumab to a VEGF-targeted tyrosine kinase inhibitor we are seeing powerful anticancer responses, including improved survival and…across broad subgroups of patients,” said lead investigator Thomas Powles, MD, PhD, FRCP, Professor of Urology Oncology, Barts Cancer Institute, London, England. “In my opinion, these data suggest that pembrolizumab plus axitinib should be a new standard of care for this population,” he added.

Dr Powles presented the results from KEYNOTE-426, a randomized, open-label phase 3 clinical trial, at the 2019 Genitourinary Cancers Symposium.

KEYNOTE-426 is the first phase 3 clinical trial to show a survival benefit with a checkpoint inhibitor plus axitinib versus sunitinib in patients with metastatic RCC. At ESMO 2018, the JAVELIN 101 clinical trial showed that avelumab plus axitinib extended PFS in patients with metastatic RCC, but no survival benefit was seen.

“The combination of pembrolizumab and axitinib appears to be superior to that of avelumab and axitinib as reported in JAVELIN 101 at the 2018 meeting of ESMO,” said ASCO Expert Sumanta K. Pal, MD, Co-Director, Kidney Cancer Program, City of Hope, Duarte, CA. “The improvement in survival makes it more likely that pembro and axitinib will be preferred to avelumab and axitinib.”

KEYNOTE-426 enrolled 861 patients with clear cell metastatic RCC who had not received systemic therapy for metastatic disease. Patients were randomized at a 1:1 ratio to receive pembrolizumab 200 mg IV every 3 weeks, for a maximum of 35 cycles, plus oral axitinib 5 mg twice daily versus oral sunitinib 50 mg every day on a 4 weeks on, 2 weeks off schedule. Treatment was continued until disease progression, unacceptable toxicity, or at the investigator’s discretion.

Patients were stratified by risk group according to the International Metastatic RCC Database Consortium as having favorable-, intermediate-, or poor-risk disease and according to geographic region.

Approximately 66% of the patients had intermediate or poor risk, and 75% had metastatic disease in 2 or more organs. The median follow-up was 12.8 months.

Improved Outcomes, Increased Survival

The 12-month OS was 89.9% in the combination therapy group versus 78.3% in the sunitinib group (P = .0001). The 18-month OS rates were 82.3% versus 72.1%, respectively. The 12-month PFS was 59.6% with the combination therapy versus 41.1% with sunitinib alone; the 18-month PFS rates were 46.2% versus 32.9%, respectively. The median PFS was 15.1 months with the combination therapy versus 11.1 months with sunitinib (P = .0001).

The objective response rate was 59.3% with the checkpoint inhibitor plus axitinib versus 35.7% with sunitinib (P <.0001). The duration of response was not yet reached in the combination arm versus a median of 15.2 months with sunitinib.

Grade 3 to 5 adverse events were higher (62.9%) with the combination therapy versus sunitinib alone (58.1%). Adverse events leading to death were re­ported in 0.9% and 1.6% of patients, respectively.

The rate of treatment discontinuation was 25.9% in the combination arm (discontinuation of 1 of the drugs) versus 10.1% with sunitinib. Discontinuation of both pembrolizumab and axitinib was reported in 8.2% of patients.

Clinical Implications

“Both KEYNOTE-426 and JAVELIN 101 are practice changing,” said study discussant, Lori Wood, MD, FRCPC, Medical Oncologist, Dalhousie University, Halifax, Canada. “In 2019, we have a new standard of care. The majority of patients with clear cell advanced RCC will be eligible to receive combination therapy with a checkpoint inhibitor and axitinib.”

“But,” she noted “there are important issues to resolve. Which treatment is better? Can we afford it? And can it be safely delivered to all patients?”

AT A GLANCE

  • ❯ KEYNOTE-426 is the first phase 3 clinical trial to show a survival benefit for a checkpoint inhibitor plus axitinib versus sunitinib in patients with metastatic RCC
  • ❯ Approximately 66% of the patients had intermediate or poor risk, and 75% had metastatic disease in ≥2 organs
  • ❯ The 12-month OS was 89.9% with pembrolizumab plus axitinib versus 78.3% with sunitinib alone
  • ❯ The 18-month OS was 82.3% with pembrolizumab plus axitinib versus 72.1% with sunitinib
Related Articles
Minimal Activity with Sapanisertib in Refractory Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma
In a phase 2 study, sapanisertib did not improve outcomes in renal-cell carcinoma.
Active Therapy Improves Survival versus BSC After Disease Progression on Nivolumab and Cabozantinib
2021 Year in Review - Renal-Cell Carcinoma
In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib.
Real-World Treatment Patterns Have Drastically Changed Over the Past 5 Years
2021 Year in Review - Renal-Cell Carcinoma
Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country